X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4318) 4318
Book Review (453) 453
Newsletter (342) 342
Publication (182) 182
Book Chapter (14) 14
Conference Proceeding (13) 13
Newspaper Article (13) 13
Dissertation (12) 12
Government Document (7) 7
Magazine Article (5) 5
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3403) 3403
male (2702) 2702
flutamide (2546) 2546
humans (2214) 2214
animals (1465) 1465
flutamide - pharmacology (1172) 1172
prostatic neoplasms - drug therapy (1039) 1039
female (1020) 1020
rats (829) 829
flutamide - therapeutic use (807) 807
aged (803) 803
prostate cancer (797) 797
androgen antagonists - therapeutic use (750) 750
androgen antagonists - pharmacology (713) 713
urology & nephrology (690) 690
middle aged (649) 649
testosterone (594) 594
endocrinology & metabolism (574) 574
prostatic neoplasms - pathology (558) 558
orchiectomy (541) 541
carcinoma (530) 530
cancer (522) 522
oncology (520) 520
flutamide - administration & dosage (493) 493
abridged index medicus (487) 487
androgens (470) 470
antineoplastic agents, hormonal - therapeutic use (394) 394
research (377) 377
androgen receptor (365) 365
aged, 80 and over (340) 340
testosterone - pharmacology (339) 339
prostate-specific antigen - blood (332) 332
mice (321) 321
care and treatment (315) 315
receptors, androgen - metabolism (315) 315
therapy (315) 315
androgen antagonists - administration & dosage (312) 312
adult (302) 302
flutamide - adverse effects (294) 294
testosterone - blood (294) 294
prostatic neoplasms - therapy (292) 292
rats, sprague-dawley (286) 286
pharmacology & pharmacy (272) 272
treatment outcome (267) 267
flutamide - analogs & derivatives (255) 255
dihydrotestosterone - pharmacology (251) 251
analysis (248) 248
dose-response relationship, drug (248) 248
prostatic neoplasms - blood (245) 245
time factors (245) 245
castration (239) 239
pregnancy (239) 239
prostatic neoplasms - surgery (235) 235
combined modality therapy (234) 234
antiandrogen (231) 231
toxicology (229) 229
antiandrogens (228) 228
antineoplastic combined chemotherapy protocols - therapeutic use (228) 228
prostatic neoplasms - mortality (228) 228
androgen antagonists - adverse effects (221) 221
expression (218) 218
androgen (215) 215
prostate (213) 213
androgens - pharmacology (202) 202
estrogen (199) 199
anilides - therapeutic use (197) 197
drugs (190) 190
adenocarcinoma - drug therapy (189) 189
universities and colleges (186) 186
trial (185) 185
neoplasm staging (184) 184
anilides - pharmacology (182) 182
drug therapy, combination (182) 182
nitriles (181) 181
bicalutamide (179) 179
follow-up studies (179) 179
rat (178) 178
tosyl compounds (178) 178
receptors, androgen - genetics (174) 174
estradiol - pharmacology (172) 172
cells (171) 171
prostate - drug effects (171) 171
hormones (169) 169
antineoplastic agents, hormonal - administration & dosage (166) 166
testis - drug effects (166) 166
organ size - drug effects (162) 162
reproductive biology (161) 161
biochemistry & molecular biology (158) 158
health aspects (152) 152
prospective studies (152) 152
hirsutism (151) 151
prostatectomy (150) 150
rats, wistar (149) 149
finasteride (147) 147
luteinizing hormone - blood (147) 147
radical prostatectomy (147) 147
gene expression (144) 144
prostatic neoplasms - metabolism (144) 144
survival rate (142) 142
cyproterone-acetate (139) 139
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4394) 4394
Spanish (70) 70
Japanese (64) 64
French (48) 48
German (33) 33
Russian (32) 32
Chinese (27) 27
Italian (17) 17
Polish (6) 6
Ukrainian (6) 6
Bulgarian (2) 2
Czech (2) 2
Hungarian (2) 2
Portuguese (2) 2
Danish (1) 1
Dutch (1) 1
Persian (1) 1
Slovak (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 06/2009, Volume 360, Issue 24, pp. 2516 - 2527
A current standard treatment for locally advanced prostate cancer is external-beam radiotherapy combined with 3 years of androgen suppression. Adverse events,... 
PHASE-III TRIAL | DEPRIVATION THERAPY | IRRADIATION | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | EORTC | RANDOMIZED-TRIAL | QUALITY-OF-LIFE | RADIOTHERAPY | RADIATION-THERAPY | ADJUVANT | Anilides - therapeutic use | Prostatic Neoplasms - radiotherapy | Follow-Up Studies | Anilides - adverse effects | Humans | Middle Aged | Male | Gonadotropin-Releasing Hormone - analogs & derivatives | Flutamide - adverse effects | Treatment Failure | Aged, 80 and over | Adult | Flutamide - therapeutic use | Prostatic Neoplasms - drug therapy | Drug Administration Schedule | Proportional Hazards Models | Combined Modality Therapy | Prostatic Neoplasms - mortality | Disease-Free Survival | Tosyl Compounds - adverse effects | Heart Diseases - mortality | Tosyl Compounds - therapeutic use | Quality of Life | Radiotherapy, Conformal - adverse effects | Aged | Androgen Antagonists - administration & dosage | Androgen Antagonists - adverse effects | Nitriles - adverse effects | Nitriles - therapeutic use | Heart attacks | Medical treatment | Mortality | Radiation therapy | Prostate cancer | Cancer therapies | Quality of life | Index Medicus | Abridged Index Medicus | Androgen Antagonists | Anilides | Life Sciences | Prostatic Neoplasms | Flutamide | Heart Diseases | Radiotherapy, Conformal | Gonadotropin-Releasing Hormone | Nitriles | Tosyl Compounds | Cancer
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 10/2016, Volume 121, p. 737
In this study, we report the synthesis and anti-proliferative effect of a set of eight androst-4-ene-3-one derivatives with different arylcarbamoyl groups at... 
Testosterone | Finasteride | Flutamide | Ketoconazole
Journal Article
Biochemical Pharmacology, ISSN 0006-2952, 12/2017, Volume 145, Issue C, pp. 178 - 191
Cytochrome P450 1A2 (CYP1A2) is one of the most abundant and important drug metabolizing enzymes in human liver. However, little is known about the... 
MicroRNA | Toxicity | hsa-miR-132-5p | Drug metabolizing enzymes | CYP1A2 | CANCER PATIENTS | CYTOCHROME-P450 1A2 | FLUTAMIDE | PROLIFERATION | BREAST | HUMAN LIVER-CELLS | METABOLISM | PHARMACOLOGY & PHARMACY | CARCINOMA | DRUG-INTERACTION | Gene Expression Regulation, Enzymologic - drug effects | Lansoprazole - pharmacokinetics | Proton Pump Inhibitors - pharmacology | Humans | MicroRNAs - metabolism | Gene Expression Regulation, Enzymologic - physiology | RNA, Messenger - metabolism | Antineoplastic Agents, Hormonal - pharmacokinetics | Proton Pump Inhibitors - administration & dosage | Computer Simulation | Cytochrome P-450 CYP1A2 - genetics | Lansoprazole - administration & dosage | Cell Line | Antineoplastic Agents, Hormonal - pharmacology | RNA Processing, Post-Transcriptional - drug effects | Antineoplastic Agents, Hormonal - administration & dosage | RNA, Messenger - genetics | Cell Proliferation - physiology | Cytochrome P-450 CYP1A2 - metabolism | Flutamide - pharmacology | Proton Pump Inhibitors - pharmacokinetics | Lansoprazole - pharmacology | Cell Proliferation - drug effects | MicroRNAs - genetics | Flutamide - administration & dosage | Flutamide - pharmacokinetics | Liver cancer | Epigenetic inheritance | Liver | Genomics | Cytochrome P-450 | Genetic research | Genetic transcription | Health savings accounts | Index Medicus
Journal Article
Journal of Investigative Surgery, ISSN 0894-1939, 2018, pp. 1 - 8
The aim of this study was to identify a theoretical support for the prevention of urethral fistula following hypospadias repair, by comparing the preputial... 
hypospadias | flutamide | prepuce | fistula
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2018, Volume 36, Issue 11, pp. 1080 - 1087
PurposeDocetaxel added to androgen-deprivation therapy (ADT) significantly increases the longevity of some patients with metastatic hormone-sensitive prostate... 
ANDROGEN-DEPRIVATION THERAPY | ONCOLOGY | MEN | FLUTAMIDE | DNA-REPAIR | CASTRATION | DOCETAXEL | ORIGINAL REPORTS
Journal Article
Journal Article
The Journal of Dermatology, ISSN 0385-2407, 02/2019, Volume 46, Issue 2, pp. e52 - e54
Journal Article
Journal Article
Journal Article
The Lancet Oncology, ISSN 1470-2045, 11/2018, Volume 19, Issue 11, pp. 1504 - 1515
Journal Article